ID   HCC1569
AC   CVCL_1255
SY   HCC-1569; Hamon Cancer Center 1569
DR   BTO; BTO:0006090
DR   CLO; CLO_0003640
DR   EFO; EFO_0001173
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   ATCC; CRL-2330
DR   BioSample; SAMN03471817
DR   BioSample; SAMN03473137
DR   BioSample; SAMN10987921
DR   cancercelllines; CVCL_1255
DR   Cell_Model_Passport; SIDM00878
DR   ChEMBL-Cells; CHEMBL3308497
DR   ChEMBL-Targets; CHEMBL1075456
DR   Cosmic; 687477
DR   Cosmic; 907046
DR   Cosmic; 1136354
DR   Cosmic; 1176644
DR   Cosmic; 1287886
DR   Cosmic; 1603204
DR   Cosmic; 1935007
DR   Cosmic; 1995425
DR   Cosmic; 2165006
DR   Cosmic; 2787232
DR   Cosmic-CLP; 907046
DR   DepMap; ACH-000930
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 907046
DR   GEO; GSM186718
DR   GEO; GSM186719
DR   GEO; GSM217575
DR   GEO; GSM219971
DR   GEO; GSM274679
DR   GEO; GSM344381
DR   GEO; GSM344431
DR   GEO; GSM350503
DR   GEO; GSM481315
DR   GEO; GSM783966
DR   GEO; GSM847323
DR   GEO; GSM847474
DR   GEO; GSM844545
DR   GEO; GSM887041
DR   GEO; GSM888111
DR   GEO; GSM1053726
DR   GEO; GSM1172959
DR   GEO; GSM1172867
DR   GEO; GSM1374501
DR   GEO; GSM1374502
DR   GEO; GSM1401674
DR   GEO; GSM1669848
DR   IARC_TP53; 10272
DR   KCLB; 71569
DR   KCLB; 9S1569
DR   LiGeA; CCLE_878
DR   LINCS_HMS; 50210
DR   LINCS_LDP; LCL-1480
DR   PharmacoDB; HCC1569_480_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1255
DR   PubChem_Cell_line; CVCL_1255
DR   SLKBase; 3530
DR   Wikidata; Q54881587
RX   PubMed=9288768;
RX   PubMed=9833771;
RX   PubMed=9865903;
RX   PubMed=11314036;
RX   PubMed=17157791;
RX   PubMed=18516279;
RX   PubMed=19582160;
RX   PubMed=20164919;
RX   PubMed=20679594;
RX   PubMed=22460905;
RX   PubMed=23151021;
RX   PubMed=23601657;
RX   PubMed=24094812;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=26759240;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/HCC1569.html
WW   https://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/cell-lines.pdf
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Doubling time: 45.43 hours (GrayJW panel).
CC   HLA typing: A*30:04,68:02; B*53:01,58:01; C*04:01,15:05 (PubMed=25960936).
CC   HLA typing: A*30:04,68:02; B*53:01,58:01; C*04:01,15:05; DQB1*06:02,06:02; DRB1*13:03,13:03 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1100Thr (c.3299A>C); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val1862fs*1 (c.5578delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 3701; FHIT; Simple; p.Val97Phe (c.289G>T) (651G>T); dbSNP=rs139666727; Zygosity=Heterozygous; Note=Germline (PubMed=9288768).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Heterozygous (PubMed=9865903; Cosmic-CLP; DepMap).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=80.08%; Native American=0%; East Asian, North=2.86%; East Asian, South=0%; South Asian=0%; European, North=4.32%; European, South=12.74% (PubMed=30894373).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=20679594; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11,12 (Cosmic-CLP; PubMed=25877200)
ST   CSF1PO: 11,12 (ATCC; PubMed=20679594)
ST   D13S317: 12
ST   D16S539: 11,12 (PubMed=20679594)
ST   D16S539: 11,12,13 (ATCC; PubMed=25877200)
ST   D16S539: 12,13 (Cosmic-CLP)
ST   D18S51: 17,18,19
ST   D21S11: 28
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 8,8.3,9 (ATCC)
ST   D7S820: 8,9 (Cosmic-CLP; PubMed=20679594; PubMed=25877200)
ST   D8S1179: 12,14,15
ST   FGA: 19.2,24
ST   Penta D: 8
ST   Penta E: 16,17
ST   TH01: 7
ST   TPOX: 6,11
ST   vWA: 17
DI   NCIt; C4017; Breast ductal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 41
//
RX   PubMed=9288768;
RA   Ahmadian M., Wistuba I.I., Fong K.M., Behrens C., Kodagoda D.R.,
RA   Saboorian M.H., Shay J.W., Tomlinson G.E., Blum J., Minna J.D.,
RA   Gazdar A.F.;
RT   "Analysis of the FHIT gene and FRA3B region in sporadic breast cancer,
RT   preneoplastic lesions, and familial breast cancer probands.";
RL   Cancer Res. 57:3664-3668(1997).
//
RX   PubMed=9833771; DOI=10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L;
RA   Gazdar A.F., Kurvari V., Virmani A.K., Gollahon L., Sakaguchi M.,
RA   Westerfield M., Kodagoda D.R., Stasny V., Cunningham H.T., Wistuba I.I.,
RA   Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.;
RT   "Characterization of paired tumor and non-tumor cell lines established
RT   from patients with breast cancer.";
RL   Int. J. Cancer 78:766-774(1998).
//
RX   PubMed=9865903;
RA   Wistuba I.I., Behrens C., Milchgrub S., Syed S., Ahmadian M.,
RA   Virmani A.K., Kurvari V., Cunningham T.H., Ashfaq R., Minna J.D.,
RA   Gazdar A.F.;
RT   "Comparison of features of human breast cancer cell lines and their
RT   corresponding tumors.";
RL   Clin. Cancer Res. 4:2931-2938(1998).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619.1-619.14(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26759240; DOI=10.1158/0008-5472.CAN-15-2201;
RA   Nakanishi Y., Walter K., Spoerke J.M., O'Brien C., Huw L.Y.,
RA   Hampton G.M., Lackner M.R.;
RT   "Activating mutations in PIK3CB confer resistance to PI3K inhibition
RT   and define a novel oncogenic role for p110beta.";
RL   Cancer Res. 76:1193-1203(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//